Related Experiment Video
Updated: Apr 10, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Successful treatment of mast cell activation syndrome with sunitinib
Lawrence B Afrin1, Frank M Cichocki1, Kamal Patel2
1Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA.
Abstract:
Mast cell (MC) activation syndrome (MCAS) is a recently recognized, likely prevalent collection of heterogeneous illnesses of inappropriate MC activation with little to no MC neoplasia likely driven by heterogeneous patterns of constitutively activating mutations in MC regulatory elements including various tyrosine kinases (TKs, dominantly KIT). MCAS typically presents as chronic multisystem polymorbidity of generally inflammatory ± allergic theme. As with indolent systemic mastocytosis (SM), treatment of MCAS focuses more against MC mediators than MC neoplasia, but some cases prove refractory even to the TK inhibitor (TKI) imatinib reported useful both in uncommon SM cases not bearing SM's usual imatinib-resistant KIT-D816V mutation and in some cases of MCAS (which rarely bears KIT-D816V). Most allergy is principally a MC activation phenomenon and sunitinib is a multitargeted TKI shown helpful in controlling a murine model of oral allergy syndrome. We present the first report of use of sunitinib in life-threatening MCAS refractory to multiple agents including imatinib achieving immediate, complete, sustained, non-toxic remission suggesting a new option for treatment of aggressive MC disease.
Insights
Sunitinib effectively treated severe Mast Cell Activation Syndrome (MCAS) refractory to other therapies. This tyrosine kinase inhibitor offers a new treatment option for aggressive MCAS, achieving complete and sustained remission.
Area of Science:
- Immunology
- Pharmacology
Background:
- Mast Cell Activation Syndrome (MCAS) involves inappropriate mast cell activation, presenting as chronic multisystem inflammatory or allergic symptoms.
- Current treatments for MCAS, like imatinib, are tyrosine kinase inhibitors (TKIs), but some cases are refractory.
- Mast cell activation is central to allergic responses, and TKIs show potential in managing these conditions.
Observation:
- The study reports the first use of sunitinib, a multi-targeted TKI, in a patient with life-threatening MCAS.
- The patient's MCAS was refractory to multiple prior treatments, including imatinib.
- Sunitinib was administered to address the aggressive nature of the disease.
Findings:
- Sunitinib achieved immediate, complete, sustained, and non-toxic remission in the patient with refractory MCAS.
- This response suggests sunitinib's efficacy in managing severe cases of MCAS.
- The treatment's success indicates a potential new therapeutic avenue for aggressive mast cell disorders.
Implications:
- Sunitinib represents a promising new treatment option for aggressive Mast Cell Activation Syndrome.
- This finding could lead to improved outcomes for patients with MCAS refractory to existing therapies.
- Further research into sunitinib's role in MCAS and other mast cell disorders is warranted.
More Related Videos
06:43Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
10:38Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Published on: December 16, 2022
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...